Ron Philip
InvestorBoard Member at Avalo Therapeutics
About
Executive Chair of CREATE Medicines pioneering targeted multi-immune therapies. Previously President and CEO of Orbital Therapeutics (acquired by Bristol Myers Squibb). Held successive leadership roles at Spark Therapeutics culminating in CEO, leading launch of LUXTURNA® (first FDA-approved gene therapy for genetic disease) and positioning the company for acquisition by Roche. Earlier experience includes decade at Pfizer and Wyeth in senior global leadership roles.
Colleagues at Avalo Therapeutics
Aaron Kantoff
Board Member at Avalo Therapeutics
Aaron Kantoff
Managing Partner at Scion Life Sciences
Amy Conrad
Senior Events Manager at Volta Labs
Amy Conrad
Director of Events & Community Engagement at Volta
Ashley Ivanowicz
Senior Vice President, Human Resources at Avalo Therapeutics
Chris Sullivan
Chief Financial Officer at Avalo Therapeutics
Colleen Matkowski
Senior Vice President, Global Regulatory Affairs and Quality Assurance at Avalo Therapeutics
Dino C. Miano
Senior Vice President, CMC and Technical Operations at Avalo Therapeutics
Frequently asked questions
- Who is Ron Philip?
- Executive Chair of CREATE Medicines pioneering targeted multi-immune therapies. Previously President and CEO of Orbital Therapeutics (acquired by Bristol Myers Squibb). Held successive leadership roles at Spark Therapeutics culminating in CEO, leading launch of LUXTURNA® (first FDA-approved gene therapy for genetic disease) and positioning the company for acquisition by Roche. Earlier experience includes decade at Pfizer and Wyeth in senior global leadership roles.
- Where does Ron Philip work?
- Ron Philip is Board Member at Avalo Therapeutics.